Lercanidipino Normon

Lercanidipine Hydrochloride, the active ingredient in Lercanidipino Normon, is a calcium channel blocker presented as a tablet for oral use. It treats essential hypertension in adult patients by lowering blood pressure and reducing cardiovascular risk.

GNH USA supplies Lercanidipino Normon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipino Normon is a calcium channel blocker indicated for the management of hypertension and related cardiovascular conditions.

- Essential hypertension: lowers systolic and diastolic blood pressure to achieve target levels. - Isolated systolic hypertension: helps control elevated systolic pressure, especially in older adults. - Hypertension with coronary artery disease: reduces cardiac workload while maintaining coronary perfusion.

Lercanidipino Normon may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Flushing: warm sensation, usually on the face or neck. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness. - Tachycardia: increased heart rate. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema: swelling of lips, tongue, or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: elevated liver enzymes. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac arrhythmias: irregular heart rhythms.

When prescribing Lercanidipino Normon, clinicians should consider several safety measures.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Hepatic impairment: use with caution; dose adjustment may be required. - Concomitant antihypertensives: assess risk of additive blood‑pressure lowering effects. - Sudden discontinuation: taper gradually to prevent rebound hypertension. - Pregnancy and lactation: evaluate risk‑benefit; limited data available. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lercanidipino Normon can interact with several drug classes, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels and risk of toxicity. - Grapefruit juice: can markedly raise drug concentration. - Concurrent use with other potent antihypertensives: may cause severe hypotension.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Non‑dihydropyridine calcium channel blockers: additive cardiovascular effects. - Diuretics: monitor electrolytes and renal function. - Beta‑blockers: watch for bradycardia or excessive blood‑pressure reduction.